glp3 retatrutide Reta (GLP-3) 20mg Retatrutide ( GLP-3 ) in

Prescriptions for GLP-1 medications more than doubled for weight management use alone in 18 months

Tirzepatide (Mounjaro, Zepbound) activates GLP-1 and GIP receptors

Patients considering these treatments should discuss their individual risk profile with their prescribing clinician, particularly if they have a history of pancreatic disease

What do clinical studies say about retatrutides effectiveness

Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management